|
Indications And Usage To Reduce The Development Of Drug-Resistant Bacteria And Maintain The E Ffectiveness Of Metronidazole Injection Usp And Other Antibacterial Drugs, Metronidazole Injection Usp Should Be Used Only To Treat Or Prevent Infections That Are Proven Or Strongly Suspected To Be Caused By Susceptible Bacteria. When Culture And Susceptibility Information Are Available, They Should Be Considered In Selecting Or Modifying Antibacterial Therap Y. In The Absence Of Such Data, Local Epidemiology And Susceptibility Patterns May Contribute To The Empiric Selection Of Therapy. Treatment Of Anaerobic Infections Metronidazole Injection Usp Is Indicated In The Treatment Of Serious Infections Caused By Susceptible Anaerobic Bacteria. Indicated Su Rgical Procedures Should Be Performed In Conjunction With Metronidazole Injection Usp Therapy. In A Mixed Aerobic And Anaerobic Infection, Antibiotics Appropriate For The Treatment Of The Aerobic Infection Should Be Used In Addition To Metronidazole Injection Usp. Metronidazole Injection Usp Is E Ffective In Bacte Roides Fragilis Infections Resistant To Clindamycin, Chloramphenicol, And Penicillin. Intra-Abdominal Infections , Including Peritonitis, Intra-Abdominal Abscess, And Liver Abscess, Caused By Bacte Roides Species Including The B. Fragilis Group ( B. Fragilis , B. Distasonis , B. Ovatus , B. Thetaiotaomic Ron , B. Vulgatus ), Clostridium Species, Eubacterium Species, Peptococcus Species, And Peptost Reptococcus Species. Skin And Skin Structure Infections Caused By Bacte Roides Species Including The B. Fragilis Group, Clostridium Species, Peptococcus Species, Peptost Reptococcus Species, And Fusobacterium Species. Gynecologic Infections , Including Endometritis, Endomyometritis, Tubo-Ovarian Abscess, And Post-Su Rgical Vaginal Cu Ff Infection, Caused By Bacteroides Species Including The B. Fragilis Group, Clostridium Species, Peptococcus Species, And Peptost Reptococcus Species. Bacterial Septicemia Caused By Bacte Roides Species Including The B. Fragilis Group And Clostridium Species. Bone And Joint Infections , As Adjunctive Therap Y, Caused By Bacte Roides Species Including The B. Fragilis Group. Central Nervous System (Cns) Infections , Including Meningitis And Brain Abscess, Caused By Bacte Roides Species Including The B. Fragilis Group. Lower Respiratory Tract Infections , Including Pneumonia, Empyema, And Lung Abscess, Caused By Bacte Roides Species Including The B. Fragilis Group. Endocarditis Caused By Bacte Roides Species Including The B. Fragilis Group. Prophylaxis The Prophylactic Administration Of Metronidazole Injection Usp Preoperativel Y, Intraoperativel Y, And Postoperatively May Reduce The Incidence Of Postoperative Infection In Patients Unde Rgoing Elective Colorectal Surgery Which Is Classified As Contaminated Or Potentially Contaminated. Prophylactic Use Of Metronidazole Injection Usp Should Be Discontinued Within 12 Hours After Surgery. If There Are Signs Of Infection, Specimens For Cultures Should Be Obtained For The Identification Of The Causative Organism(S) So That Appropriate Therapy May Be Given (See Dosage And Administr Ation ). To Reduce The Development Of Drug-Resistant Bacteria And Maintain The E Ffectiveness Of Metronidazole And Other Antibacterial Drugs, Metronidazole Should Be Used Only To Treat Or Prevent Infections That Are Proven Or Strongly Suspected To Be Caused By Susceptible Bacteria. When Culture And Susceptibility Information Are Available, They Should Be Considered In Selecting Or Modifying Antimicrobial Therapy. In The Absence Of Such Data, Local Epidemiology And Susceptibility Patterns May Contribute To The Empiric Selection Of Therapy.
|